CoChat

Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor-positive breast cancer

Open access

Published version of a preprint

The DOI matches its Crossref record; 53 of the 55 references it cites were found in a registry or an index.

Abstract

Abstract Purpose: Although cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors significantly extend tumor response in patients with metastatic estrogen receptor–positive (ER+) breast cancer, relapse is almost inevitable. This may, in part, reflect the failure of CDK4/6 inhibitors to induce apoptotic cell death. We therefore evaluated combination therapy with ABT-199 (venetoclax), a potent and selective BCL2 inhibitor. Experimental Design: BCL2 family member expression was assessed following treatment with endocrine therapy and the CDK4/6 inhibitor palbociclib. Functional assays were used to determine the impact of adding ABT-199 to fulvestrant and palbociclib in ER+ breast cancer cell lines, patient-derived organoid (PDO), and patient-derived xenograft (PDX) models. A syngeneic ER+ mouse mammary tumor model was used to study the effect of combination therapy on the immune system. Results: Triple therapy was well tolerated and produced a superior and more durable tumor response compared with single or doublet therapy. This was associated with marked apoptosis, including of senescent cells, indicative of senolysis. Unexpectedly, ABT-199 resulted in Rb dephosphorylation and reduced G1–S cyclins, most notably at high doses, thereby intensifying the fulvestrant/palbociclib–induced cell-cycle arrest. Interestingly, a CRISPR/Cas9 screen suggested that ABT-199 could mitigate loss of Rb (and potentially other mechanisms of acquired resistance) to palbociclib. ABT-199 did not abrogate the favorable immunomodulatory effects of palbociclib in a syngeneic ER+ mammary tumor model and extended tumor response when combined with anti-PD1 therapy. Conclusions: This study illustrates the potential for targeting BCL2 in combination with CDK4/6 inhibitors and supports investigation of combination therapy in ER+ breast cancer.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-1872

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 53 references

Cited by

See all 102

Metadata

Authors
Whittle, J. R., Vaillant, F., Surgenor, E., Policheni, A. N., Giner, G., Capaldo, B. D., Chen, H.-R., Liu, H. K., Dekkers, J. F., Sachs, N., Clevers, H., Fellowes, A., Green, T., Xu, H., Fox, S. B., Herold, M. J., Smyth, G. K., Gray, D. H. D., Visvader, J. E., & Lindeman, G. J.
Affiliations
  • The University of Melbourne (AU)
  • Walter and Eliza Hall Institute of Medical Research (AU)
  • Royal Netherlands Academy of Arts and Sciences (NL)
  • Peter MacCallum Cancer Centre (AU)
Venue
Clinical Cancer Research
Published
2020-08-01
Volume
26
Issue
15
Pages
4120-4134
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3015152600
Cited by
102
References
55
Citations by year
2026: 15 · 2025: 10 · 2024: 10 · 2023: 20 · 2022: 21 · 2021: 20 · 2020: 6
FWCI
9.43
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Funders
  • National Health and Medical Research Council (1054618, 1113133, 1153049)
  • National Breast Cancer Foundation (NT-13-06, IIRS-19-004)
  • Breast Cancer Research Foundation (BCRF-18-182)
  • Cancer Australia (1165878)
  • Qualtrough Cancer Research Fund Joan Marshall Breast Cancer Research Fund Collie Foundation (2017F001)
  • NHMRC (1090236, 1158024, 1058892, 1037230, 1078730, 1175960)
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
estrogen receptor-positive breast cancer, CDK4/6 inhibitors, BCL-2 inhibition, venetoclax, palbociclib, fulvestrant, combination therapy, senolysis, Rb dephosphorylation, acquired drug resistance, immunomodulation, anti-PD-1 therapy, patient-derived xenografts, patient-derived organoids
MeSH terms
Fulvestrant, Adult, Aged, Animals, Antineoplastic Combined Chemotherapy Protocols, Breast, Breast Neoplasms, Disease Models, Animal, Female, Humans, Mastectomy, Middle Aged, Organoids, Piperazines, Pyridines, Receptors, Estrogen, Sulfonamides, Chemotherapy, Adjuvant, Apoptosis, Drug Resistance, Neoplasm, Bridged Bicyclo Compounds, Heterocyclic, Proto-Oncogene Proteins c-bcl-2, Neoadjuvant Therapy, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Primary Cell Culture

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor-positive breast cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1872
The paper
Whittle, J. R., Vaillant, F., Surgenor, E., Policheni, A. N., Giner, G., Capaldo, B. D., Chen, H.-R., Liu, H. K., Dekkers, J. F., Sachs, N., Clevers, H., Fellowes, A., Green, T., Xu, H., Fox, S. B., Herold, M. J., Smyth, G. K., Gray, D. H. D., Visvader, J. E., & Lindeman, G. J. (2020). Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor-positive breast cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1872

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.